• 20% reduction in annual operational loss
• Cash of €4.1 million as of December 31, 2023
Toulouse, FRANCE, Lakeland, UNITED STATES, March 11, 2024, 7:30 a.m. CET – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), next generation biotechnology company dedicated to the discovery and development of innovative therapies based on the only recombinant human apolipoprotein apoA-I in the world, today presents its 2023 annual results as approved by all the members of the board of directors and provides an update on its activity to date. The audit procedures on the consolidated accounts have been carried out. The certification report has not been issued to date. It will be issued after finalizing the procedures required for the purposes of filing the universal registration document.
To receive information from ABIONYX Pharma in real time, send a request to [email protected].